{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-25-000088","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.378275+00:00","generated_at":"2026-05-17T18:20:33.348770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed","bullets":["Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.","Completed dose finding and confirmed RP2D for Phase 1 SENTI-202 trial in AML; now in dose expansion.","Received FDA Orphan Drug Designation for SENTI-202 in AML.","Received $1.0M from CIRM grant; added Bryan Baum to Board, Dr. James Trager to Scientific Advisory Board.","Expect additional efficacy and durability data from SENTI-202 Phase 1 study in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-25-000088","json":"https://secwatch.observer/filing/0001854270-25-000088.json","markdown":"https://secwatch.observer/filing/0001854270-25-000088.md","text":"https://secwatch.observer/filing/0001854270-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/0001854270-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/snti-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:20:33.348770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}